About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/10/2020.
 Menu
This website is for US healthcare professionals
close-icon

Log In to Bolder Science

logo-iconLog in with Doximity
or
Forgot Password

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

logo-iconLog in with Doximity
or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Specialties

Choose 1 or more specialties that you are interested in:

Subspecialties

You can specify a subspecialty for areas you selected (if available):

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/10/2020.
Previous Next skip
Our Science

    • CC-93269 (Anti-BCMA T-Cell Engager)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Proposed Mechanism of Action

    CC-93269 is an investigational, humanized IgG1-based 2+1 T-cell engager (TCE) designed to bind to B-cell maturation antigen (BCMA) on malignant and non-malignant plasma cells and CD3ε on T cells, thus coupling both cell types.1,2 This simultaneous binding is proposed to result in T-cell activation and cytokine release, followed by cytolytic synapse formation and secretion of cytolytic enzymes.1,2

    `

    CC-93269 by Disease State

    CC-93269 in Multiple Myeloma

    Phase 1
    Relapsed/refractory

    View Trials Investigating CC-93269 in Multiple Myeloma
    View Rationale for Clinical Development

    Rationale for Clinical Development

    BCMA is a promising target for the treatment of multiple myeloma using various investigational modalities, such as a TCE, because it is universally expressed on the surface of malignant and non-malignant plasma cells and is essential for the survival of these cells.1,3,4 Preclinical studies have shown that anti-BCMA TCEs may cross-link T cells with BCMA-expressing cells, including malignant myeloma cells, potentially leading to increased immune antitumor activity via redirected killing of myeloma and healthy plasma cells by autologous T cells.1,2 Preclinical studies are ongoing to optimize, improve, and assess the potential benefits and risks of CC-93269 as a single agent therapy or in combination with other therapies in multiple myeloma.

    View Related Pathways

    T-Cell Engagers
    B-Cell Maturation Antigen (BCMA)

    References

    1. Seckinger A, et al. Cancer Cell. 2017;31:396-410. PMID: 28262554
    2. Vu MD, et al. Blood. 2015;126:2998.
    3. Tai YT, Anderson KC. Immunotherapy. 2015;7:1187-1199. PMID: 26370838
    4. Carpenter RO, et al. Clin Cancer Res. 2013;19:2048-2060. PMID: 23344265